GlassScriptPhysician profile
Robert A Zajac
NPI 1013907963
$9,689.42
in general payments reported to CMS, 2019-2025
32 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,041 · 2020: $2,844 · 2021: $1,436 · 2022: $826 · 2023: $616 · 2024: $487 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517 · Education: $26.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.50 |
| Education | $26.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $2,041.35 | 2020-2021 | |
| Viiv Healthcare Company | $1,812.77 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $1,133.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $726.25 | 2019-2023 | Dificid, Delstrigo |
| Abbvie INC. | $725.75 | 2021-2025 | Teflaro, Avycaz, Dalvance |
| Janssen Biotech, INC. | $526.83 | 2019-2023 | Symtuza |
| Allergan, INC. | $514.54 | 2019-2020 | |
| Grifols USA, LLC | $337.64 | 2019-2024 | Gamunex-C |
| Paratek Pharmaceuticals, INC. | $239.96 | 2019-2025 | Nuzyra |
| Theratechnologies INC. | $233.77 | 2019-2023 | Trogarzo, Egrifta |
| Insmed, INC. | $193.31 | 2020-2025 | Arikayce |
| Octapharma USA, INC. | $110.10 | 2021-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Ferring Pharmaceuticals INC. | $98.75 | 2023 | Rebyota |
| Shionogi INC | $95.45 | 2020-2024 | Fetroja |
| Cumberland Pharmaceuticals, INC. | $91.04 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $82.23 | 2021 | |
| Aimmune Therapeutics, INC. | $79.26 | 2024-2025 | Vowst |
| Pfizer INC. | $75.09 | 2020-2023 | |
| Csl Behring | $66.09 | 2020-2021 | |
| Napo Pharmaceuticals INC | $65.81 | 2019 | |
| Emd Serono, INC. | $62.48 | 2020-2021 | |
| Melinta Therapeutics, LLC | $61.04 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $58.49 | 2019 | |
| La Jolla Pharmaceutical Company | $42.64 | 2020-2021 | |
| Adma Biomanufacturing LLC | $42.24 | 2021 | |
| Vyera Pharmaceuticals, LLC | $36.57 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $33.38 | 2019 | |
| Shire North American Group INC | $28.12 | 2019 | |
| Pharming Healthcare, INC. | $26.00 | 2024 | |
| Smith+Nephew, INC. | $19.69 | 2020 | |
| Antares Pharma, INC. | $15.67 | 2019 | |
| Aytu Biopharma, INC. | $13.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Zajac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.